‘Evidence supports’ de-escalating combination therapy in patients with IBD after 1 year

DENVER — Providers should consider de-escalating combination therapy with immunomodulators to monotherapy after 1 year in patients with inflammatory bowel disease, according to a presenter at the Crohn’s and Colitis Congress.“We know that combination therapy is one of our most, if not the most, effective therapies: not the combination of biologics, but the combination of the thiopurine and anti-tumor necrosis factor medications, and everyone knows the seminal SONIC trial, infliximab and thiopurines were superior to both monotherapies,” Ryan C. Ungaro, MD, MS, associateRead More